Response to “Lupus anticoagulant is frequent in patients with Covid‐19” (JTH‐2020‐00483)

Zhang, 2020, Coagulopathy and antiphospholipid antibodies in patients with Covid‐19, N Engl J Med, 382, e38, 10.1056/NEJMc2007575

Taylor, 2001, Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation, Thromb Haemost, 86, 1327, 10.1055/s-0037-1616068

Pengo, 2009, Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis, J Thromb Haemost, 7, 1737, 10.1111/j.1538-7836.2009.03555.x

Ledford‐Kraemer, 2014

Góralczyk, 2015, False‐positive lupus anticoagulant in patients receiving rivaroxaban: 24 h since the last dose are needed to exclude antiphospholipid syndrome, Blood Coagul Fibrinolysis, 26, 473, 10.1097/MBC.0000000000000235